Trends in HEOR: What Payers and HTA Bodies Are Asking for Now
A therapy can clear every regulatory hurdle and still face difficult questions at the formulary or reimbursement stage. That gap between regulatory approval and patient access is where health economic ...
The Evolution of HEOR in Rare Diseases: From Cost-Effectiveness to Strategic Market Access
There used to be a simple rule in pharma: scientists built the drug, clinical teams proved it worked, and health economists showed up near the end to do the math. Run the trial, demonstrate efficacy, ...